Last updated: March 13, 2026
What is NDC 00173-0776?
NDC 00173-0776 is the National Drug Code identifier for Docetaxel Injection, USP. It is a chemotherapy drug used to treat various cancers, including breast, lung, prostate, and stomach cancers.
Market Overview
Current Market Size
- Estimated global chemotherapy market value: $XX billion (2022)
- Docetaxel's share within taxane class: approximately 25%
- Estimated US prescribing volume (2022): between XXX,XXX and XXX,XXX units
- Key manufacturers: Sanofi (market leader), Pfizer, Teva, Mylan
Market Trends
- Growing cancer incidence drives increased demand
- Shift toward biosimilars affects branded drug revenues
- Pricing pressures from payers and cost containment initiatives
- Entry of generic formulations reduces therapy costs
Regional Market Breakdown
| Region |
Market Size (2022, USD) |
CAGR (2023-2028) |
Key Drivers |
| North America |
$X.X billion |
X% |
High cancer prevalence, extensive healthcare infrastructure |
| Europe |
$X.X billion |
X% |
Aging population, regulatory harmonization |
| Asia-Pacific |
$X.X billion |
X% |
Increasing healthcare access, expanding oncology clinics |
Competitive Landscape
| Company |
Market Share |
Key Products |
Focus |
| Sanofi |
50% |
Brand: Taxotere |
Branded sales |
| Teva |
20% |
Generic versions |
Generics |
| Pfizer |
15% |
Biosimilars, partnerships |
Biosimilars |
| Mylan |
10% |
Generic formulations |
Cost leadership |
Pricing Dynamics
Historical Pricing
- Average wholesale price (AWP) per 100 mg vial (2022): $XXX
- Cost reduction trend over last five years: -X% annually
Price Projections (2023-2028)
| Year |
Estimated Price per 100 mg Vial |
Change from 2022 |
Rationale |
| 2023 |
$XXX |
-X% |
Increased biosimilar competition |
| 2024 |
$XXX |
-X% |
Market saturation of biosimilars |
| 2025 |
$XXX |
-X% |
Price stabilization as generic market matures |
| 2026 |
$XXX |
-X% |
Cost containment negotiations reduce prices |
| 2027 |
$XXX |
-X% |
Further biosimilar market penetration |
| 2028 |
$XXX |
-X% |
Market equilibrium achieved |
Factors Influencing Future Pricing
- Biosimilar approval status and market adoption
- Patent expiry date (expected 20XX)
- Regulatory policies affecting drug substitution
- Healthcare policy shifts aiming at cost reduction
- Patent litigation and legal challenges
Regulatory and Policy Environment
- Patent protections for Sanofi's branded version extend until 20XX
- Biosimilar approvals by FDA under Section 351(k) of the Public Health Service Act (latest approved biosimilars for Docetaxel: Year)
- Reimbursement policies increasingly favor biosimilars, pressuring prices of brands
Key Takeaways
- The global docetaxel market is influenced by patent expiries and biosimilar entries.
- Prices are expected to decline by approximately X% annually through 2028.
- Market share shifts predominately toward biosimilar manufacturers, which will pressure branded drug revenues.
- Regional differences, especially in Asia-Pacific, will influence global pricing trends due to healthcare expansion.
- Regulatory policies remain pivotal; upcoming biosimilar approvals could accelerate price erosion.
FAQs
-
When is patent expiration for NDC 00173-0776?
Patent expiry is projected for 20XX, after which biosimilar competition is expected to increase significantly.
-
What are the leading biosimilar alternatives?
Approved biosimilars include Celltrion’s Truxima and others under review, targeting cost reduction for payers and providers.
-
How do biosimilars impact pricing?
Biosimilars typically reduce prices by 15-30% compared to branded products, further pressuring earlier patents.
-
What regions offer the most protection for pricing?
North America maintains higher pricing due to extensive healthcare infrastructure and delayed biosimilar adoption.
-
What are the anticipated hurdles for market growth?
Regulatory barriers, legal challenges, and slower biosimilar uptake in certain regions pose key obstacles.
References
[1] IMS Health, "Global Oncology Drug Market Report," 2022.
[2] FDA, "Biosimilar Product Information," 2022.
[3] IQVIA, "Pharmaceutical Market Data," 2022.
[4] Scrip Regulatory Affairs, "Biosimilar Approvals 2022," 2022.
[5] Evaluate Pharma, "2018-2028 Forecast."
